The Indiana Opioid Epidemic and Minority Impact
Join Side Effects Public Media & The Indiana Minority Health Coalition for a virtual town hall conversation. The conversation will focus on Indiana's opioid epidemic and its impact on minorities. There will be a panel conversation followed by time for Q&A. This event will be available through a live stream. The participation link will be emailed to all registrants a week beforehand.
When: February 13, 2018, 10:30 a.m. – 12:00 p.m.
Where: Virtual Panel Discussion
Follow this link to register: https://www.eventbrite.com/e/the-indiana-opioid-epidemic-and-minority-impact-tickets-41762054429
Pills, Bills & Policy
December 12, 2017 Prescription Drug Monitoring and Opioid Prescribing Guidelines
This was the first Side Effects Public Media event in a series about opioids and their impact on Indiana. The topic was prescription drug monitoring programs, prescription guidelines and pain management. You can find our reporting related to this topic here and here.
Kicking off this event was Jim McClelland who serves as the Executive Director for Drug Prevention, Treatment, and Enforcement for the State of Indiana. This presentation focused on an overview of the opioid epidemic and its impact in Indiana. Mr. McClelland spoke about how Indiana is dealing with this complex problem by leveraging resources strategically to make a positive impact. He also touched on legislation and the state’s work in regards to prescription guidelines and Indiana’s prescription drug monitoring program INSPECT.
Dr. Chris Harle is an associate professor in the Department of Health Policy and Management at the IU Fairbanks School of Public Health. In his presentation entitled “Opioid Prescribing Decisions: Patients, Providers, Pain and Prescription Drug Monitoring Programs” , Dr. Harle shares research and data highlighting workflows and challenges for clinicians.
Lastly is the panel discussion followed by a Q&A session. This panel explores how Indiana can help health care providers manage patients’ pain without fueling addition, with an emphasis on prescription drug monitoring programs, how they are used, and what potential they have.